- Home
- ACLX
ACLX
Arcellx Inc.
as 12-12-2024 10:30am EST
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 5.3B | IPO Year: | 2022 |
| Target Price: | $104.46 | AVG Volume (30 days): | 458.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $47.88 - $107.37 | Next Earning Date: | 11-07-2024 |
| Revenue: | $155,818,000 | Revenue Growth: | 230.33% |
| Revenue Growth (this year): | 10.41% | Revenue Growth (next year): | -9.43% |
Stock Insider Trading Activity of Arcellx Inc. (ACLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Kavita | ACLX | Director | Dec 3 '24 | Sell | $92.02 | 1,500 | $137,817.72 | 0 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Nov 15 '24 | Sell | $90.93 | 1,761 | $156,508.43 | 100 | |
| Patel Kavita | ACLX | Director | Nov 12 '24 | Sell | $106.33 | 1,500 | $159,495.00 | 0 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Nov 8 '24 | Sell | $101.29 | 12,354 | $1,242,170.45 | 100 | |
| Patel Kavita | ACLX | Director | Nov 7 '24 | Sell | $102.92 | 57,479 | $5,971,808.80 | 0 | |
| Patel Kavita | ACLX | Director | Oct 22 '24 | Sell | $89.69 | 1,500 | $134,535.00 | 0 | |
| Patel Kavita | ACLX | Director | Oct 1 '24 | Sell | $82.24 | 1,500 | $123,360.00 | 0 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Sep 17 '24 | Sell | $77.69 | 15,000 | $1,165,879.57 | 100 |
Latest Arcellx Inc. News
ACLX Breaking Stock News: Dive into ACLX Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
2 days ago
ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma
MT Newswires
2 days ago
Gilead Sciences, Arcellx's CAR-T Therapy Supports 2030 Oncology Ambitions, Oppenheimer Says
MT Newswires
2 days ago
UBS Raises Price Target on Arcellx to $114 From $106, Maintains Buy Rating
Investor's Business Daily
3 days ago
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
MT Newswires
3 days ago
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
MT Newswires
3 days ago
Sector Update: Health Care
Benzinga
3 days ago
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
MT Newswires
3 days ago
Arcellx Says Trial of Multiple Myeloma Drug Candidate Achieves 97% Overall Response Rate
Compare ACLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACLX Arcellx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.